Impact of Protocol Deviations in Acute Ischemic Stroke Treated With Intravenous rt-PA Within 4.5 Hours After Symptom Onset

The Neurohospitalist

Volumn 2, Issue 3, 2012, Pages 82-86

  Alderazi, Y J ^a   Chang, J ^b   Chapple, K ^b   Yang, J P ^c   Teleb, M ^d   Awad, A ^e   Restrepo, Lucas ^f  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY   (United States)

^e ARIZONA STATE UNIVERSITY   (United States)

^f UCLA MEDICAL CENTER   (United States)

Author keywords

cerebrovascular disorders; outcomes; quality; safety; stroke; techniques

Indexed keywords

EID: 84890357107     PISSN: 19418744     EISSN: 19418752     Source Type: Journal    
DOI: 10.1177/1941874412441802     Document Type: Article

References (14)

1. The ATLANTIS, ECASS, NINDS rt-PA Study Group Investigators, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004; 363(9411):768–774.
2. Hacke W Kaste M Bluhmki E etal; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359(13):1317–1329.
3. Saver JL Gornbein J Grotta J, et al. Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window: joint outcome table analysis of the ECASS 3 trial. Stroke. 2009; 40(7):2433–2437.
4. Wahlgren N Ahmed N Dávalos A etal; SITS investigators. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 2008; 372(9646):1303–1309.
5. Lansberg MG Bluhmki E Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a meta analysis. Stroke. 2009; 40(7):2438–2441.
6. Del Zoppo GJ Saver JL Jauch EC etal; American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009; 40(8):2945–2948.
7. Bluhmki E Chamorro A Dávalos A, et al. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009; 8(12):1095–1102.
8. Alshekhlee A Mohammadi A Mehta S, et al. Is thrombolysis safe in the elderly?: analysis of a national database. Stroke. 2010; 41(10):2259–2264.
9. Adams HP Jr Bendixen BH Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24(1):35–41.
10. Williams LS Yilmaz EY Lopez-Yunez AM. Retrospective assessment of initial stroke severity with the NIH Stroke Scale. Stroke. 2000; 31(4):858–862.
11. Vemmos K Ntaios G Spengos K, et al. Association between obesity and mortality after acute first-ever stroke. Stroke. 2011; 42(1):30–36.
12. J⊘rgensen HS Nakayama H Reith J Raaschou HO Olsen TS. Acute stroke with atrial fibrillation: the copenhagen stroke study. Stroke. 1996; 27(10):1765–1769.
13. Tung CE Win SS Lansberg MG. Cost-effectiveness of tissue-type plasminogen activator in the 3- to 4.5-hour time window for acute ischemic stroke. Stroke. 2011; 42(8):2257–2262.
14. Minnerup J Wersching H Ringelstein EB, et al. Impact of the extended thrombolysis time window on the proportion of recombinant tissue-type plasminogen activator-treated stroke patients and on door-to-needle time. Stroke. 2011; 42(10):2838–2843.